# Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy Subjects

> **NCT05540912** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 30 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** D064+D701
- **DRUG:** CKD-828 Formulation 1
- **DRUG:** CKD-828 Formulation 2

## Key facts

- **NCT ID:** NCT05540912
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-15
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-12-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05540912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05540912, "Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05540912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*